Replies to post #234755 on Biotech Values

[miljenko]

Chart looks terrible, and Comp. may be *terrible* as well!

[DewDiligence]

WVE—(-29%/AH)—discontinues entire HD program:

https://finance.yahoo.com/news/wave-life-sciences-provides-phase-200500861.html

In the PRECISION-HD2 core trial, results from all participants (n=88) showed no statistically significant change in mutant huntingtin protein (mHTT) versus placebo after single or multiple doses of WVE-120102 up to and including 32 mg monthly. There was no evidence of a dose response across the dose levels tested.

…Results in all participants through 16 mg (n=51) from the PRECISION-HD1 core trial are similar to those in PRECISION-HD2 at those dose levels. Given these and results from Wave’s previous clinical trials, as well as current understanding of the limitations of the company’s first-generation candidates, Wave will also stop clinical development of WVE-120101.